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Abstract We conducted ethnographic research in collaboration with a large, research-
intensive London breast cancer service in 2013–2014 so as to understand the
practices and potential effects of stratiﬁed medicine. Stratiﬁed medicine is often
seen as a synonym for both personalised and precision medicine but these three
terms, we found, also related to distinct facets of treatment and care. Personalised
medicine is the term adopted for the developing 2016 NHS England Strategy, in
which breast cancer care is considered a prime example of improved biological
precision and better patient outcomes. We asked how this biologically stratiﬁed
medicine affected wider relations of care and treatment. We interviewed formally
33 patients and 23 of their carers, including healthcare workers; attended meetings
associated with service improvements, medical decision-making, public
engagement, and scientiﬁc developments as well as following patients through
waiting rooms, clinical consultations and other settings. We found that the
translation of new protocols based on biological research introduced further
complications into an already-complex patient pathway. Combinations of new and
historic forms of stratiﬁcation had an impact on almost all patients, carers and
staff, resulting in care that often felt less rather than more personal.
Keywords: UK, personalised medicine, breast cancer, ethnography, stratiﬁcation, healthcare
markets
Introduction
Stratiﬁed medicine is a term that has been widely used since the 1990s in relation to genomics
and subsequently other ﬁelds of biology. It is a form of medicine that sorts a population into
the most biologically appropriate groupings to determine the optimal therapeutic response.
However, this approach can also be described both as personalised and as precision medicine.
The former term has been adopted by NHS England for their forthcoming Strategy (2016) and
the latter in the USA in President Obama’s Precision Medicine Initiative (2015). Both these
government initiatives stress how such developments will replace the previous ‘one size ﬁts
all’ or ‘trial and error’ approach to medicine and health care in the same way as proponents of
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stratiﬁed medicine. Precision medicine builds on the ﬁner sub-classiﬁcation of disease to add
repeated monitoring of disease markers to enable recursive tailoring of treatment to individual
response. Personalised medicine can be used to incorporate both the more precise biological
stratiﬁcation and a holistic approach, which accords a role to patient participation and prefer-
ence (Cribb and Owens 2010). As Tutton (2012, 2014) has emphasised, consideration of the
dual biological and social aspects of health care has a long history in the UK, which may
explain why the term ‘personalised medicine’ is most commonly used. In this article, we use
stratiﬁed medicine as a cover term as it is more inclusive of other forms of biological differen-
tiation which pre-date the newer terms; we use the terms precision and personalised medicine
only when they are speciﬁcally intended.
Stratiﬁed medicine is strongly supported by the UK government through funding for the life
sciences and drug development as well as the National Health Service (NHS). Thus, the UK
Medical Research Council’s 2014–2019 research strategy emphasises the possibilities of strati-
ﬁed, personalised and precision medicine and the Secretary of State for Health announced
Genomics England in 2013, explaining:
The UK will become the ﬁrst ever country to introduce this technology in its mainstream
health system – leading the global race for better tests, better drugs and above all better,
more personalised care to save lives. (Genomics England 2013)
In order to explore the translation of stratiﬁed medicine into existing systems and the possibili-
ties of a more personalised care, we focused on cancer services where some diseases are now
subdivided into several biological groupings. For example, 10 or more types of breast cancer
were described in 2012 (Curtis et al. 2012), conﬁrming that breast cancer is a heterogeneous
disease at the genetic level. These types respond to different treatments, and experimental and
translational cancer research are woven together with standard cancer care in ways that have
become more complex since the ‘-omics revolution’. (Keating and Cambrosio 2007, 2011,
2012a, 2012b)
Breast tumours are staged according to their size and anatomical spread, and graded by histo-
logical appearance; molecular typing improves estimates of prognosis and the likely beneﬁts of
different therapies. Subtyping includes histological grade, the expression of hormone receptors
(oestrogen and progesterone) and the ampliﬁcation status of the HER2 gene. Additional molecu-
lar tests may be performed to distinguish subtypes that might beneﬁt from different therapies,
and combination therapies are used to address the intransigent issues surrounding drug resis-
tance. Yeo et al. emphasise the improved survival rates associated with new targeted therapies
and conclude, ‘We are on the brink of an era of diverse molecular stratiﬁcation of breast cancer,
and the development of increasingly personalised medicine’ (Yeo et al. 2014: 4).
What counts as stratiﬁed medicine is contested. Tamoxifen, a hormonal therapy initially
licensed in the UK to treat advanced breast cancer in 1972, is not commonly included because
it is not based in genomics. It has been used widely since the 1980s for oestrogen receptor
positive (ER+) cancers but, as 80% of breast cancers are ER+, further proﬁling is also required
to inform treatment strategies. Similar problems arise with even the best-known examples of a
stratiﬁed (genomic) approach. About 15% of breast cancers have ampliﬁcation of the HER2
gene (Yeo et al. 2014) and trastuzumab (brand name Herceptin), a monoclonal antibody, is
routinely given to improve disease-free survival. The use of HER2 as a biomarker has become
a key stratifying diagnostic, which is intrinsic to decisions about therapy. This biomarker
reﬂects somatic change in the tumour and is targeted by trastuzumab, but it is not inherited by
transmission of a germ-line mutation, as is the case with BRCA1 and BRCA2 and so its status
in the new stratiﬁed medicine has also been disputed (Hedgecoe 2005).
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Since the draft sequence of the Human Genome Project, scholars and commentators have
explored the hope, promise and anticipation as well as the scepticism surrounding personalised
genomics and its institutionalisation in health care. Social research has explored the role of
speculation and of expectations that might bring the future into the present along with the nec-
essary collaborations, resources and infrastructure to deliver this new medicine. Some have
explored this in relation to increasing the markets for treatments (Gabe et al. 2012), introduc-
ing the notion of surplus health (Dumit 2012), including the promise of modern genomics in
relation to the increasing prominence of bio-sociality and labour market opportunities in out-
sourced clinical trials (Fortun 2008, Sunder Rajan 2006). Others have looked at health care in
relation to the move from ‘bench to bedside’, observing that knowledge and practice travel in
more than one direction, enrol companions along the way and produce, at least from the per-
spective of researchers and industry, unanticipated results (Hedgecoe 2006, 2008). These con-
tributions have illuminated developments in industry and marketing, including the growth of
online genetic testing, new companion diagnostics associated with targeted therapies (‘thera-
nostics’) and shifting medical aetiologies. Less sociological attention has been devoted to the
mundane business of integrating new practices of medicine within existing services, although
Hedgecoe (2004, 2008) has explored the use of pharmacogenetics in the clinic, including
genetic tests.
Some research-intensive units, where statiﬁed medicine is developed and implemented, have
below-average ratings in patient experience surveys (see for example Quality Health 2013).
We undertook a small pilot evaluation of patients’ experience in a large, research-intensive
cancer unit. We analysed survey responses from 777 patients and carried out 25 hours of
observation in the services, observing and talking to 28 patients, 14 companions and 10 staff.
We were struck by the complexity of patients’ journeys, involving multiple and repeated visits
to different elements of the service for detailed diagnosis, monitoring and treatment. Problems
arose when the ‘system’ did not work in drawing all these elements together and patients were
left feeling vulnerable and wondering, ‘who is thinking of me when I am not here?’
On the basis of this pilot, we hypothesised that stratiﬁed medicine might promote fragmen-
tation and depersonalised care while at the same time delivering more biologically precise
treatment. We further hypothesised that this situation resulted from medical practices that
ampliﬁed concurrent developments intensifying the stratiﬁcation of the workforce and the mar-
ket. We therefore designed a study to examine how recent developments were embedded in a
large London breast cancer service in the light of sociological attention to the -omics revolu-
tion as well as the translation of new medical knowledge and practices.
Methods
We conducted an ethnographic study to explore the translation of stratiﬁed medicine to the
‘shop ﬂoor’ of cancer services in a research-intensive London hospital. Following the initial
pilot, we researched breast cancer, the largest tumour group, combining observation with inter-
views from 2013 to 2014. Staff and patients contributed to the study design, and the study
included interviews of patients and staff about their experiences. The study had ethical and
local regulatory approval (London, City and East Research Ethics Committee 12/LO/0685,
Imperial College London Joint Research Ofﬁce).
The study was advertised through staff meetings, posters and leaﬂets in the hospital site and
two local non-government organisations (NGO). We focused our observations on a large out-
patient department (clinic) that acted as a hub, bringing together many specialised staff,
patients, carers, researchers and NGO workers such as Macmillan Cancer Support staff. This
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clinic also provided the main site for recruiting research participants to interview. Patients were
informed about the study by clinical staff and introduced to researchers on site or asked to
contact the research team by e-mail or phone. Eligible patients (≥ 18 years of age and receiv-
ing treatment or follow-up care for breast cancer) were provided with information about the
study by clinical staff and through publicity, and those who volunteered to participate in inter-
views were asked for their written consent. They were then invited to complete two interviews,
3–6 months apart. Patients who were interviewed were also asked to name people who had
been central to their care, ‘key individuals’ (who may have been companions, family, friends
or NGO or healthcare staff), and to approach them with invitations to participate in the study.
Staff were also recruited through advertising posters and staff meetings. These other partici-
pants (key individuals) were asked for their consent in the same way as the patients but to a
single interview. We interviewed the patients, carers and staff about their own experiences of
the cancer services using minimal structured prompts from a topic guide.
Observations and interviews were carried out by four researchers (SD, LM, CS and HW),
who kept extensive ﬁeld notes of the observations and conversations. The interviews were
audio-recorded, transcribed and organised using NVivo. Data were coded and checked for con-
sistency and comprehensiveness by four members of the team, who also cross-referenced inter-
view material to ﬁeld notes by date and theme so as to construct a single data set.
Key themes were identiﬁed and discussed in monthly team meetings before coding, enabling
a shared foundation for continuing ﬁeldwork. Where appropriate, material was also discussed
and checked with staff in the breast cancer service. The integration of these varied data
enabled fuller interpretation: interview material was extended by observations of participants
across different settings, while ﬁeldwork notes were elaborated in the light of individual views
and explanations. The analytic approach is common to ethnographic studies insofar as it
frames what people say they do in relation to what they are observed to do (Bernard 2006),
acknowledging the inﬂuence that social positions will have on differing perspectives of a wide
range of clinical, administrative and other activities.
Results
We observed 75 half-day sessions in the cancer services; most were in a large outpatient
department (OPD, clinic) but we also spent time in the chemotherapy unit and in multidisci-
plinary team meetings. In total 33 patients were recruited and 23 were re-interviewed between
February 2013 and April 2014.1 Re-interviews allowed us to check our original information
and to extend our understanding of the patient’s journey in a situation of increasing rapport.
We also interviewed 23 key individuals, again with their written consent. Most of these 79
interviews lasted 50–70 minutes and took place in the hospital or ofﬁces of a neighbouring
NGO; two were conducted at the participant’s home. Patients participating in interviews ran-
ged in age from 38 to 79 years (median: 58.7 years) and most were white (n = 26). Most
were being treated for the ﬁrst occurrence of breast cancer (n = 22) and had begun treatment
fewer than 5 years previously (n = 23). Key individuals participating in interviews included
eight family/friends; 14 healthcare staff: nurses, doctors and ancillary staff; and one NGO
worker.
We found that the terms, stratiﬁed, precision and personalised medicine were used rarely. In
order to assess the translation of stratiﬁed method into routine care, therefore, we begin with
the meetings at which these terms were introduced and discussed before turning to understand-
ings of the patient pathway or journey. We use ‘HER2’ as an exemplar of the new approach
in clinical consultations that we observed.
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Stratiﬁed medicine: the promise of genomics
There is so much going on, like building cathedrals in the Middle Ages. Molecular science
is so exciting. (Oncologist, 2013)
Direct reference to stratiﬁed medicine was observed spontaneously only in meetings, some of
which included events for patients and the public. In these meetings, developments in biology
provided the foundations of a vision that would lead to better treatment and care, indicating
how references to biology implicate other matters (Hacking 2007). An oncologist and cancer
scientist explained the future for a new centre at one such event, pointing to facilities for gen-
ome sequencing and drug testing. He emphasised how critical this multidisciplinary perspec-
tive had been to the development of new drugs and methods of detection, as indicated by our
paraphrased ﬁeld notes:
New translational research from genome studies of the code is critical. . .. This is very
important because cancer is strictly Darwinian. People die not because they’re not sensitive
to treatment. . . 90% of women will respond. Women die however because tiny numbers of
cells in any cancer are dislodged into the blood stream, and mutations in DNA overcome
the blockage imposed by the drug. Now the drugs exist to kill 99.9% of sensitive cells but
the remaining 0.1% cells survive. It’s not the drugs that create mutations; they were there
from the beginning. Previously, you needed a lump of tissue to sequence a genome. Soon
you will have the whole genome sequenced commercially from a single cell.
The speaker described how selective drugs (unlike standard chemotherapy) inhibit speciﬁc pro-
teins in the metabolic pathways associated with cancers. However, a small number of pre-
existing mutations will be drug resistant and so the therapy will select for their growth. Later
on, the speaker provided an illustration from work on BRCA proteins, underscoring the impor-
tance of heterogeneity in cancers. In answer to a question, he explained that inhibition of the
enzyme that helps mend broken bits of DNA should have led the cancer cells to die. However,
they grew out with this inhibitor because the sub-clone had been there from the beginning,
and so the cancer cell survived. He continued:
Should we add extra drugs to the cocktail? Now, we guess and we use three or four drugs
at the outset. It will take another ﬁve years, perhaps a total period of 15 years, to develop
combination treatments at the outset that are more than guesswork. Cancer is so clever but
we will be able to overcome it eventually so that it will become more like diabetes. We’ll
sequence in a blood test for an emerging clone. [He describes the current situation and con-
tinues] If we can, we’ll turn cancer from a very frightening and aggressive illness to a
chronic illness that we monitor before the lumps ever appear. This is more than a vision.
(Oncologist, 2013; paraphrased notes from meeting)
This promissory vision that will turn breast cancer into a more benign condition diagnosed by
a blood test and treated before ‘lumps’ form has been extensively analysed in relation to con-
temporary developments in biocapital as well as the sociology of speculation (see Dumit 2012,
Fortun 2008, Gabe et al. 2012, Sunder Rajan 2006: see also Good 2001). It is important to
appreciate, too, how this optimism enrols staff as well as patient participation, and motivates
career choices and subsequent practice. We found that many healthcare workers responded to
the new science with reﬂections on their own encounters with illness. Subsequently, some spe-
cialised in cancer care or research, while others volunteered to work with patients. Another
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inspiring account from an oncologist, again for non-specialists, indicates the attraction of this
atmosphere; here speaking of the earlier introduction of tamoxifen in the way that oncologists
speak of trastuzumab or similar drugs today:
I became interested in endocrine therapy when I qualiﬁed. . .. [A] patient, who had been
there for 6 months with mental health issues, was physically sick. This turned out to be
breast cancer but no-one had examined her. In those days, there were no physician oncolo-
gists and oncology was a Cinderella specialty. . . And so I became interested in oncology
and especially in breast cancer where there was a new drug on the block called tamoxifen.
This we gave to her and she got better. The breast cancer melted away and she recovered
mentally too because the hormone that the cancer cells were producing was gone. And she
returned home and to a normal life. . .. There is so much going on, like building cathedrals
in the Middle Ages. Molecular science is so exciting. (Oncologist, 2013; paraphrased notes
from meeting)
The presentation of a new biology that promised a better future was typical of a wide range of
meetings we attended, and this vision is congruent with the developing NHS England Strategy
for Personalised Medicine.
Stratiﬁed medicine: oncology out-patients
Stratiﬁed medicine was rarely mentioned in the clinic although individuals commonly spoke of
genetics and, with probing, patients referred vaguely to improved outcomes. Some spoke with
relief about an initial HER2 positive diagnosis since they had conﬁdence that trastuzumab would
help, even though the prognosis is intrinsically worse than for other types of breast cancer. A
senior nurse appeared equally nonplussed and said during a discussion of stratiﬁed medicine:
I didn’t know what you were talking about until your colleague explained the emphasis on
genomics. Medicine here and nursing just as much have always been stratiﬁed. This is noth-
ing new. (Field notes 2014)
On being questioned, the oncologists explained how stratiﬁed medicine was embedded in
everyday practice and as ordinary as previous efforts to classify patients (Hedgecoe 2004). In
this context, newly stratifying diagnostics joined older forms, linking trastuzumab and tamox-
ifen within the same routines. It was hard therefore to identify the speciﬁc forms of stratiﬁed
medicine that derived from -omics and we selected HER2 as an exemplar of the new
approach.
Patients spoke less of their particular type of cancer than of waiting. At least 2 days a week,
the large OPD had three oncology clinics in breast cancer running simultaneously, involving
approximately 10 doctors, ﬁve outpatient nurses, a specialist lymphoedema nurse with her own
clinic, clinical nurse specialists (CNS), two phlebotomists, three reception staff and a volunteer
greeting patients. Throughout our ﬁeldwork, up to a hundred patients congregated for long
periods in this OPD and interacted with these as well as other hospital and university employ-
ees, and NGO workers such as Macmillan Cancer Support staff. Patients receiving treatment
might spend most of the day at the hospital, waiting to have their bloods taken, waiting to see
an oncologist, waiting for their script to be made up in the pharmacy and waiting for a chair
in the chemotherapy suite. They might also do all this work and leave without receiving the
planned treatment but with a further appointment on the horizon. In such circumstances, some
patients asked whether the delay would affect the course of a cancer that would not wait. In
the context of a busy urban NHS service, waiting has many inﬂections: inefﬁciencies and
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bureaucratic inﬂexibility; triage; and also a form of care among those waiting and working
together. Occupying physically the OPD, patients commented both on their appreciation of an
NHS that belonged to them and also on their humiliation as they were deﬁned, contained and
put on hold by the system (Day 2015, Livingston 2012). Patients contrasted the inefﬁciencies
of the system almost universally with what they considered the uncommon kindness, admir-
able skills and excellent care on the part of individual members of staff, especially with refer-
ence to their clinical expertise.
In clinical consultations, patients’ perspectives on their type of cancer occasionally surfaced
during interactions with doctors; we therefore provide examples from clinical consultations.
A doctor told a patient who was positive for HER2 that she had metastases on her lungs:
‘yours is an unusual case; your cancer has spread while having Herceptin. That was very
unlucky’. This patient was not eligible for the new treatment trial because it would probably
give her too many side effects and the consultation concentrated on resolving what might be
an effect of the cancer and what might be a side effect of treatment or perhaps yet another
issue. Another woman learned that she had not responded to treatment. She was taken off tras-
tuzumab after ﬁve cycles as ‘she’ (that is, her cancer) was progressing and she had a tumour
in her chest. The specialist registrar said that this very unusual: ‘Most people respond’, to
which her patient replied that she wanted to be told that she’d got 20 years’ remission. An
elderly woman with metastatic cancer asked this same doctor if trastuzumab could be causing
her rhinitis. She explained ﬁrst that she could not leave the house without tissues and then
asked if the doctor could please check the tumour. It had been aching and she had been
coughing. She had various side effects and, in her words, saw a spine doctor, a diarrhoea doc-
tor and a kidney doctor, between them managing cancer in her spine, lung, spleen and kidney.
She attended this OPD every 3 weeks although, she said, ‘I have never been ill’. Having lived
with cancer and its treatments for many years, this woman declined further chemotherapy as,
she said, ‘it only has 26–28% success anyway’. She explained to the doctor that her sister had
‘nursed her husband to death through his cancer and the chemo had only made things worse’.
After some discussion, doctor and patient decided to wait for results of tumour markers before
doing anything further.
These brief examples show that cancers, therapies and people do not always behave as
expected, and failures caused surprise. Regular monitoring enabled interventions to be tailored
recursively to a changing mix of cancer, treatment, side effects and other issues, and the new
biomarkers and treatments were subject to a process of testing through trial and error just like
the old. Misunderstandings were common, as the following example on the importance of
monitoring indicates.
An oncologist explained the close attention given to repeated test results in the clinic one
day, perhaps for my (SD) beneﬁt and perhaps, too, for the beneﬁt of a patient’s granddaughter.
During the consultation, the granddaughter, a healthcare professional, asked pointed questions
to which the doctor responded; ‘ﬁrst are the blood markers, second the scanning and in her
case she’d had an X-ray and a spinal CT [computed tomography] scan, third the breast exami-
nation’. The marker was CA15–3, which half the patients had and which was also the best
possible marker. Hers was stable: ‘if you have more of them, you’ve got more cell division’.
The doctor said of the X-ray:
[W] ell, perhaps it’s a bit misleading as it was done 6 weeks before we began treatment and
so it [the shadow] would have grown before the treatment [could have] worked.
Bone scans could also mislead as they ﬂared up when they were healing; ‘it’s not a great test
to order, especially if you see a junior doctor next time and they don’t know this’. On
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examination, the doctor concluded that her tumour was softer and much less deﬁned than it
had been. He looked back over the scans and wondered if she even had a shadow in her
breastbone; there was no conﬁrmation from the CT scan, no cancer in her spine or rib, and so
he was not at all convinced by this shadow in the sternum.
Did she [the patient] want to look at the scans? ‘The scans are so accurate nowadays and
[of] such good resolution that they pick up everything. . .. [The older woman asked her
granddaughter to look instead.] You can see how small this possible shadow is in relation
to the rest here’. The patient was confused by the quantity of information but she heard her
doctor conclude, ‘no, the lump isn’t growing and all is under control’. She was not inter-
ested in the results and concluded, when she was told that she would most likely be on that
treatment for the standard 2 years, ‘well, at least that means I’ll be living for another 2
years’. (Field notes 2013)
Monitoring often led to more tests in the effort to achieve greater precision, informing deci-
sions about the next step. The sequence of steps describes a patient pathway and existing pro-
cedures have become more complex with the introduction of new practices of stratiﬁed
medicine.
Stratiﬁed medicine in the clinical pathway: implications for the division of labour
The epistemic, political, and economic status of the cancer patient within protocols and the
protocol-production process has been a recurring theme for both patients and practitioners,
especially when the time comes to choose which road to take – which path to follow or
decision to make – in that embedded series of protocols commonly referred to as the thera-
peutic process. (Keating and Cambrosio 2007: 215)
Continued monitoring can modify treatment: cancers resist or adapt and so treatment must co-
evolve to stratify and calibrate disease differently over time. The new medicine is embedded
in trials that span the world and have introduced protocols that dictate procedures seen as path-
ways (Berg 1998, Timmermans and Berg 1997). Reciprocally, as Keating and Cambrosio
(2007: 215) assert, ‘All patient pathways converge sooner or later on a protocol’. They con-
tinue:
Presently, even though few adult cancer patients actually participate in clinical trials, virtu-
ally all of them are diagnosed, treated, and advised according to a protocol, be it a routine
or an experimental protocol.
The concept of pathways arose in the 1980s. Pathways not only plot the steps to caring for
and treating patients but also a range of other requirements: they guide costing and rationing,
workﬂow and performance management as well as clinical practice (Rotter et al. 2010). From
a service perspective, the pathway is a standard built from evidence-based practice which is
addressed to groups of patients, conditions or molecular activities (strata) that are both more
and less than individuals (Zuiderent-Jerak et al. 2012). For most staff, pathways were peopled
with abstract as well as particular patients, along with their most predictable variations, who
ﬁgured in a host of requirements that were glossed simply as standards. Some of these stan-
dards referred to clinical protocols and others to government requirements that set a clock tick-
ing to a prescribed timeline and provided the basis for calculating costs and payments. For
example, a ‘14-day target’ speciﬁed the approved limit for referral from a primary care
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physician with suspicions of cancer to an appointment in a specialist clinic; and service provi-
ders would be sanctioned if they missed this target. For patients, by contrast, the pathway rep-
resented their own journey through treatment and, in interview, few appeared to know what
would or should happen next. For example, one woman spoke of the period after surgery:
This test, next test, and I had to go under that machine.. . . . For a while, I was coming in
nearly every other day. . .. When you come back, you have to go to here. You need to go
and have a scan. Then they phone you: ‘Oh, you have got to go and have this’. I spent
every other day here. . .. Every day, someone’s, ‘Go here, go there’.
The distance between views of the pathway helps to explain why no-one we interviewed could
map the whole pathway in concrete terms onto the particular hospital site.
Staff were aware that the expansion of treatment might provide ‘adaptive’ or ‘tailored’ care
and improve outcomes but they were also concerned that developments would promote differ-
entiation of the workforce, which could affect patient care negatively. As several staff
explained, stratiﬁed medicine requires specialist expertise distributed along the pathway. The
extended taxonomy of breast cancers understandably lengthens a hospital line: a patient needs
more tests and monitoring to ﬁnd the right treatment; analysis requires more biostatistical
expertise and new kinds of trials. You cannot test a stratiﬁed medicine on an unstratiﬁed popu-
lation and so fewer patients are eligible for each trial; drugs are tested in combination and bio-
logical targets constantly move. At the same time, they explained, elements of the pathway
can be delegated to non-specialists. The new biological medicine’s protocols outline ﬁxed
steps to follow according to the best evidence and so they allow less qualiﬁed staff to simply
follow instructions where processes are not yet automated, freeing experienced clinical labour
to deal with problems that arise.
These observations suggest that the new biological stratiﬁcation is one important factor pro-
moting the increasing stratiﬁcation of the workforce. Moreover, we observed that specialist clini-
cal labour was directed increasingly towards the complex technical requirements of
management. Services supporting the breast cancer pathway, which ideally run alongside clinical
care, were provided more often by autonomous NGOs such as Macmillan Cancer Support, by
volunteers and by family members.2 In practice, the increasingly elaborate division of labour can
make it very difﬁcult for patients to receive and staff to deliver the appropriate care, and any
common standard (Bowker and Star 1999) for the patient pathway is in danger of unravelling.
The separation between some support and medical services indicates the importance of a third
form of stratiﬁcation that might address the problems of integrating an increasingly fragmented
pathway, at least in the view of service leads who were responsible for improving services.
Stratiﬁed or personalised care?
The doctors do not seem to understand that it is not answers but assistance that we seek.
(Patient, 2014)
In the UK at least, stratiﬁed medicine is seen as a step along the way to a fully personalised
approach although, during ﬁeldwork, references to the latter became scarce in response to the
difﬁculties that we have described. Nonetheless, personalisation is the best known of the three
terms for the new biology, as well as for other practices in health and social care. Personal
budgets in social and some health care, for example, present the service user as a customer
who can shop around the emerging market to choose the best package of care.3
Patients expressed frustration when they were ‘lost’ or ‘missed’ because of a lack of integra-
tion along their complex pathway. A patient might need to see a surgeon, radiologist, clinical
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oncologist, plastic surgeon, chemotherapy nurse and radiographer, and some complained that
they rarely saw the same person twice. Although the UK NHS has long contained markets in
care, it is only recently (2012–2013) that the UK Health and Social Care Act opened them to
all willing providers. As a consequence, cancer services in some regions were put out for ten-
der. The UK’s main cancer charity that supports patients orchestrated one such bidding pro-
cess. According to The Guardian newspaper, Macmillan Cancer Support’s advisory role was
grounded in the desire
to overhaul cancer care in the county to make it more joined-up after some patients com-
plained that they were “getting lost in the system, having to repeat themselves all the time,
and that care [was] not always factoring in their personal circumstances.” (Campbell 2014,
our italics.)
The charity was criticised for its possibly unwitting ideological support of privatisation when a
number of ﬁrms attended their brieﬁngs. Macmillan’s chief executive responded with the claim
that the new programme would offer ‘an integrated approach’ and ‘[b]y appointing one organi-
sation to take responsibility for managing the whole cancer care journey, we can demand truly
seamless care’ (Devane 2014).
The problem of navigating complex systems has been made more acute by the requirements
of stratiﬁed medicine with its increasing specialisation and monitoring. Support along the patient
pathway has traditionally been delivered by a CNS, who meets patients at the diagnosis and
offers them support during treatment. However, the increasing complexity of the pathway and a
growing caseload had made this role more challenging. Survey results show that having a CNS
correlates with a better patient experience (Quality Health 2013). Our research participants val-
ued supportive relationships with CNS but some patients were not sure who this person was or
whether they had a named CNS at all. One, for example, could not identify a speciﬁc CNS,
referring instead to a ‘cast of thousands’ involved in her care. Another, with metastatic disease,
looked blank when asked but her husband wondered if one of three particular nurses might be a
CNS. All three were ‘very good most of the time’, ‘anything that’s wonky, they sort it out’, but
when one of them went on holiday, the couple found they were unable to reach the named alter-
native support. This particular couple also explained that they had been happy to liaise with the
consultant’s secretary, who could resolve problems when the system did not function well, but
her job had disappeared during restructuring (Ward and Day 2013).
The allocation (or subcontracting) of navigation and some supportive care to non-clinical
staff and external bodies such as charities constitutes a further form of stratiﬁcation, leaving
clinical care with the more technical and protocol-driven elements. Research participants, staff
and patients alike, expressed disquiet at the impersonal nature of many clinical interactions in
the same way as Macmillan and many bemoaned the lack of ‘generalist’ expertise that could
hold the pathway together. Clearly, these problems have not been caused directly by the trans-
lation of biological developments into health care; complaints about the impersonal nature of
bureaucracies are pervasive. However, the practices of stratiﬁed medicine have an elective
afﬁnity with both the outsourcing of particular support services and occupational specialisation,
suggesting that an indirect relationship exists between developments in these different forms of
stratiﬁcation. As far as clinicians and patients were concerned, the spaces for holistic care have
become more and more restricted.
In this context, it is worth noting a paradox recognised by a range of participants: the most
personalised medicine in the sense of both experimental biology and holistic care (Tutton
2012, 2014) was found at the limits of protocol-governed treatment where there was simply
no biological evidence and only minimal market demand. We encountered patients with
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advanced disease who were receiving palliative treatment to control their symptoms or slow
down disease progression. Chang4 fell in this group and her views changed over the course of
our year’s ﬁeldwork. Initially, she explained that her chances of recovery were slim because
there were no treatments for her ‘triple negative’ status. An ex-nurse, she was clear that she
would refuse treatment if it made her feel worse but, after some time, agreed to chemotherapy
for secondary tumours. As she explained, ‘ﬁrst they burnt my brain and now, there are just a
few strands [of hair] here and there’. Her double vision had returned. ‘Never mind’, she said,
‘this hat keeps me warm and with the scarf too’. Now, she thought, she would stop treatment
only if tests showed that the tumours were growing: there would be ‘nothing left to do’. She
spoke of a referral to a hospice and for morphine syrup but said it was too early; she was not
ready. Discussing the all-important results, Chang agreed that she, not the doctors, would
decide:
[D]octors hope; they want to carry on treatment but they are very good. . . and yes, I will
not have treatment unless it is working. What is the point?
Chang was on the last cycle of the treatment when we [SD] met again and then, she said, ‘it
is currently a full stop’. A few days later, she joked about which doctor she would see with a
fellow patient, Yuna, in the OPD. Yuna said her doctor had told her there was no answer.
Chang retorted, ‘the doctors do not seem to understand that it is not answers but assistance
that we seek’. Was Chang asking when the interventions to track and respond to biological
pathways would cease and when someone would offer her the help she needed? If dying and
living are experienced together (Das 2015), at what point should the biologically deﬁned path-
way end and how?
Although we were focusing on breast cancer, elements of the cancer pathway were shared
and we met Chris during our pilot study receiving treatment for a different tumour. A few
months later when we met again by chance, I [SD] asked about the treatment and Chris
shrugged. It was not clear, he said, and added, ‘I’m on the last shot. Anything from now on is
experimental’. Noting that ‘10 years ago, I wouldn’t have had a chance’, he acknowledged that
there was no clear evidence but a number of drugs to try. Chris was positive about his experi-
mental treatment. To be treated as a unique ‘case’ meant that there were no validated biomark-
ers or therapies but only personalised care. This personalisation was attuned to a stratum of
one but Chris, unlike Chang, considered experimentation a form of responsiveness that might
encompass the biological, the ﬁnancial, the bureaucratic or any other facet of what was always
also his singular position. If Chang saw the biological ‘personal’ in opposition to a more holis-
tic or social care, Chris considered them to be closely connected. He might have said, as Kit
did in Iain Banks’s (2013: 159) The Quarry, ‘I know Guy’s cancer is not contagious; you
can’t catch it off him. . .. That’s the thing about cancer; it’s all yours – it’s entirely, perfectly
personalised’. Paradoxically, it is only when a stratum of n = 1 is deﬁned that the biologically
personalised joins the socially personalised medicine.
Discussion
We have described how stratiﬁed medicine is experienced as it is introduced in a large research-
intensive cancer unit. While it is not possible to isolate the impact of translational medicine from
other developments in breast cancer care through an ethnographic approach, we have identiﬁed a
number of key ﬁndings. Firstly, we observed how clinicians and scientists embrace the new
molecular medicine with great optimism, anticipating the successful transformation of cancer
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management using precise diagnosis, monitoring and therapy. Secondly, stratiﬁed medicine was
seen to have placed additional strains on the service through its requirement for a highly skilled
workforce and a meticulously integrated patient pathway that, in the context of budget con-
straints, were difﬁcult to deliver. Highly skilled staff have moved increasingly to back ofﬁce
functions such as laboratory analysis, the research and testing of algorithms and the continuing
development of protocols and they have been replaced in frontline functions by less qualiﬁed
staff following the protocols of the new medicine. This leads into the third point; this recalibra-
tion of staff roles has enabled hospitals to trim budgets and carry on, but staff and patients alike
reported increasing fragmentation and particular difﬁculties in coordinating the steps along a
pathway. Finally, we show how measures to improve coordination and navigation, with the
introduction of new roles and some external providers, do not always work, with the result that
some patients describe care that is far from personalised.
If the requirements of the new medicine were not sufﬁciently exacting in the UK today, its
realisation is complicated still further by largely contingent developments that may amplify the
processes that we have observed. Elements of government, industry and research are intent on
bringing a ‘better’ medicine to the patient. Personalised medicine has been considered vari-
ously in relation to New Labour, neoliberal reforms and the new austerity (Cribb and Owens
2010, European Alliance for Personalised Medicine 2013, Savard 2013) but, with its many
associations, it can coincide with a wide range of regimes. New legislation mandating the ten-
dering of services to ‘all willing providers’ enables the outsourcing of parts of the pathway.
These developments, in turn, mean that services will be able to sustain the technical and bio-
logical work required by the new medicine. Stratiﬁed medicine may promise to create a per-
son-centred hub in place of the Fordist line that patients described, but interventions towards
this end already threaten to bring the pathway to a stop. Future outsourcing might resolve
problems in the pathway and initiate alternative directions but it could equally intensify the
direction of current developments so that staff and patients alike ﬁnd themselves in pieces,
scattered along the pathway and struggling to put the parts together.
Stratiﬁed medicine is contrasted favourably with a previous and less desirable ‘all-comer’
medicine. All-comer medicine fails to treat effectively because it treats uniformly and ‘one
size’ is intended to ‘ﬁt all’. The modernist notion of health care for all, cradle to grave, seems
inappropriate to new biologies, burgeoning expertise and consumer preferences. In the UK,
this all-comer, also known as ‘empirical’ (Hingorani et al. 2013), medicine has been practiced
in a national service that met needs through centralised planning associated with bureaucratic
inﬂexibilities and relatively effective price control. Having evolved over the last 60 years to
include all manner of quasi-public and quasi-private service providers, the NHS is considered
by some commentators to be too unwieldy to deliver personalised medicine, that is, a set of
practices that holds patients at the centre of a pathway receiving treatment that will work on
their type of cancer.
Participants in this particular cancer service were unclear about the contours of a better med-
icine that might integrate care with treatment and improved outcomes. Many spoke of ele-
ments from a pre-genomic, as well as the genomic, era and emphasised the importance of a
form of care that delivered an inclusive service. Even though the traditional NHS form of
stratiﬁcation was compromised by its association with a callous bureaucracy and a one-size-
ﬁts-all form of cancer care, patients strongly supported the admission of all-comers and they
emphasised how thrilled they were to be welcomed and treated themselves. However, the rela-
tions between an inclusive service on the one hand and improved outcomes on the other
remained hazy. The ‘better’ market form on offer was equally tainted by association with an
inappropriate or unethical proﬁt motive and, at times, a similarly vague association between
market efﬁciency, on the one hand, and better outcomes, on the other, was implied.
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Even though participants were unclear about the path to a better medicine, several expressed
concern about future lines of exclusion that would replace valued public realms, in which the
NHS continues to occupy a central place, with thoroughgoing market principles (Day 2015). In
the 21st century, valuation creates biological markets through inevitably evaluative processes of
sorting that are currently bundled under the rubric of an -omics revolution. This revolution points
to a seemingly impossible leap in cancer care where the individuation of biologies and customer
preferences will coincide with numerous other, potentially divergent measures tracking costs, gov-
ernance requirements, safety, participation on the part of both staff and patients, and, of course,
health outcomes in a single pathway. How can value become equally an outcome and an experi-
ence, a notion of inclusion or equity and a price that government, insurers or others will pay?
Conclusion
Stratiﬁed, precision and personalised medicine constitute a ﬁeld of overlapping and shifting
meanings that appeal to notions of evidence, new expertise and person-centred care as well as
subgroup medicine. Personalised medicine, conceived in terms of a welcome attention to the
person of the patient, which is exquisitely attuned to individual genetic and – by extension –
social factors, is perhaps the best known of these three terms and it is also the most ﬂuid and
contested. It remains an aspiration and, in the meantime, stratiﬁed medicine refers to and pro-
duces new forms of disease that inevitably combine with previous ones.
In one research-intensive, large, urban centre from 2013 to 2014, the translation of stratiﬁed
medicine into routine care led to a combination of practices that promoted less rather than more
integrated, personalised and seamless care. This result may describe a temporary phase of health-
care delivery and it cannot be attributed solely to the new biology. Nonetheless, the empirical
consequences of new medical practices and the elective afﬁnities that we have outlined between
developing forms of stratiﬁcation in medicine, the market and workforce suggest that the transla-
tion of -omics into standard care will have similar, unanticipated effects in other UK settings.
Expectations and the promise of biological developments are an important theme in the soci-
ological literature. However, the focus of previous studies has tended to be on the big players
– in science, industry and government, or on particular perspectives within the translational
pathway. By observing and integrating the perspectives of the many different players involved
with stratiﬁed medicine in health care we have shown that high expectations of the new strati-
ﬁed medicine are widely shared by participants who are often considered to have distinct views
and interests, with health care staff on the one side and patients with their families and friends
on the other. Furthermore, speculation about a better future is embedded in everyday interac-
tions within the service. In this context, the mundane challenges we have discovered to the
introduction of stratiﬁed medicine may prove difﬁcult to reconcile with widespread optimism.
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Notes
1 Of the original sample, four were either too unwell or had died, one could not be reached and ﬁve
declined a second interview.
2 Research participants alluded to support services closely associated with the hospital journey such as
volunteers in the OPD and chemotherapy suite, carers who accompanied patients and three particular
NGO, one that operated within as well as outside the hospital and two local services. These support
services had independent sources of funding. When interviewed about their journey more generally,
patients spoke of a much wider range of support.
3 For example, one provider describes their plans for personal care budgets, ‘This is a completely dif-
ferent approach to an historic ‘one size ﬁts all’ system of individuals having to access, and ﬁt into,
care and support services that already exist which have been designed and commissioned on their
behalf by Local Authorities for example. Individuals will receive their own budget and can
decide how, who with and where they wish to spend that budget in order to meet their needs and
achieve their desired outcomes. Whilst there is initial focus on social care and support services, the
principles of personalisation are being embedded into a range of other public service areas such as
health and education.’ (Skills for Care 2016).
4 Names (pseudonyms) are used in examples where it helps the reader to follow the narrative.
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